Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00599638 · ClinicalTrials.gov registry record · Phase 2
A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT00599638 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 72 participants.
The verdict
NCT00599638, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
Pregabalin is an alpha-2 delta ligand approved for the treatment of neuropathic pain, however, not all patients will respond to this drug. This study will compare the efficacy of pregabalin when administered with an experimental drug PF-00489791, in patients with post-herpetic neuralgia. The efficacy of this combination will be compared to pregabalin alone.
Interventions
- DRUG Placebo
- DRUG pregabalin
- DRUG pregabalin/PF-00489791
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2008-04-09 |
| Est. Completion | 2008-12-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00599638
The ClinicalTrials.gov registry entry for NCT00599638 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00599638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00599638 about?
NCT00599638 is a clinical study titled "A Study To Compare Pregabalin/PF-00489791 Combination Versus Pregabalin Alone In Post-Herpetic Neuralgia". Pregabalin is an alpha-2 delta ligand approved for the treatment of neuropathic pain, however, not all patients will respond to this drug. This study will compare the efficacy of pregabalin when administered with an experimental drug PF-00489791, in patients with post-herpetic neuralgia. The efficac...
What is the current status of trial NCT00599638?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2008-04-09. Estimated completion is 2008-12-23.
What interventions are being tested in trial NCT00599638?
The interventions under investigation include: Placebo (DRUG), pregabalin (DRUG), pregabalin/PF-00489791 (DRUG).
Who is sponsoring clinical trial NCT00599638?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.